This HTML5 document contains 48 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n18http://localhost/temp/predkladatel/
n7http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n16http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
n5http://linked.opendata.cz/ontology/domain/vavai/riv/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
n10http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216208%3A11140%2F10%3A10282033%21RIV15-MSM-11140___/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n19http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n8http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n6http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n13http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216208%3A11140%2F10%3A10282033%21RIV15-MSM-11140___
rdf:type
skos:Concept n16:Vysledek
rdfs:seeAlso
http://ejcts.oxfordjournals.org/content/38/1/91.full.pdf+html
dcterms:description
Objective: Minimised perfusion circuits (MPCs) are expected to reduce the side effects of conventional cardiopulmonary bypass (CCPB); however, conclusive data from sufficiently powered clinical trials are lacking. The purpose of this study was to evaluate the safety and efficacy of the ROCsafeRX (TM) minimised perfusion circuit. Methods: A randomised, controlled, multicentre clinical trial comparing both perfusion circuits in patients subjected to elective coronary artery bypass and/or aortic valve replacement is described. The primary end points of safety, defined as procedure success without device-related complications, and secondary end point of efficacy, including reduction of transfusion requirement and incidence of atrial fibrillation, are analysed. Results: To date, 291 patients have been enrolled and randomised (146 MPC vs 145 CCPB). With the exception of a significantly higher male population in the MPC group (83.6% vs 71.0%, p = 0.01), both groups were well matched for demographic data and type of surgery. There were no device-related complications but a hard-shell reservoir had to be integrated in one MPC because of a tear in the right atrium that was managed uneventfully. Total transfusion requirement (329 +/- 599 ml vs 783 +/- 1638 ml, p {= 0.001) and erythrocyte transfusion (181 +/- 341 ml vs 434 +/- 798 ml, p {= 0.001) were significantly reduced in the MPC group. The incidence of atrial fibrillation was significantly lower in the MPC group (7.1% vs 19.5%, p {= 0.01), while freedom of major adverse events showed no significant difference. Conclusions: Lack of device-related complications combined with a significant reduction in postoperative atrial fibrillation and transfusion requirements have shown the ROCsafeRX (TM) MPC to be both safe and efficient for large-scale use in cardiac patients. Additional data are expected to confirm these initial findings. (C) 2010 European Association for Cardio-Thoracic Surgery. Objective: Minimised perfusion circuits (MPCs) are expected to reduce the side effects of conventional cardiopulmonary bypass (CCPB); however, conclusive data from sufficiently powered clinical trials are lacking. The purpose of this study was to evaluate the safety and efficacy of the ROCsafeRX (TM) minimised perfusion circuit. Methods: A randomised, controlled, multicentre clinical trial comparing both perfusion circuits in patients subjected to elective coronary artery bypass and/or aortic valve replacement is described. The primary end points of safety, defined as procedure success without device-related complications, and secondary end point of efficacy, including reduction of transfusion requirement and incidence of atrial fibrillation, are analysed. Results: To date, 291 patients have been enrolled and randomised (146 MPC vs 145 CCPB). With the exception of a significantly higher male population in the MPC group (83.6% vs 71.0%, p = 0.01), both groups were well matched for demographic data and type of surgery. There were no device-related complications but a hard-shell reservoir had to be integrated in one MPC because of a tear in the right atrium that was managed uneventfully. Total transfusion requirement (329 +/- 599 ml vs 783 +/- 1638 ml, p {= 0.001) and erythrocyte transfusion (181 +/- 341 ml vs 434 +/- 798 ml, p {= 0.001) were significantly reduced in the MPC group. The incidence of atrial fibrillation was significantly lower in the MPC group (7.1% vs 19.5%, p {= 0.01), while freedom of major adverse events showed no significant difference. Conclusions: Lack of device-related complications combined with a significant reduction in postoperative atrial fibrillation and transfusion requirements have shown the ROCsafeRX (TM) MPC to be both safe and efficient for large-scale use in cardiac patients. Additional data are expected to confirm these initial findings. (C) 2010 European Association for Cardio-Thoracic Surgery.
dcterms:title
A prospective randomised multicentre clinical comparison of a minimised perfusion circuit versus conventional cardiopulmonary bypass A prospective randomised multicentre clinical comparison of a minimised perfusion circuit versus conventional cardiopulmonary bypass
skos:prefLabel
A prospective randomised multicentre clinical comparison of a minimised perfusion circuit versus conventional cardiopulmonary bypass A prospective randomised multicentre clinical comparison of a minimised perfusion circuit versus conventional cardiopulmonary bypass
skos:notation
RIV/00216208:11140/10:10282033!RIV15-MSM-11140___
n5:aktivita
n6:V
n5:aktivity
V
n5:cisloPeriodika
1
n5:dodaniDat
n13:2015
n5:domaciTvurceVysledku
n7:4473604 n7:8164649
n5:druhVysledku
n15:J
n5:duvernostUdaju
n19:S
n5:entitaPredkladatele
n12:predkladatel
n5:idSjednocenehoVysledku
244888
n5:idVysledku
RIV/00216208:11140/10:10282033
n5:jazykVysledku
n8:eng
n5:klicovaSlova
Transfusion requirements; Aortic valve replacement; Coronary artery bypass; Minimised perfusion circuits
n5:klicoveSlovo
n9:Aortic%20valve%20replacement n9:Minimised%20perfusion%20circuits n9:Transfusion%20requirements n9:Coronary%20artery%20bypass
n5:kodStatuVydavatele
NL - Nizozemsko
n5:kontrolniKodProRIV
[9A0FA27AA4F6]
n5:nazevZdroje
European Journal of Cardio-thoracic Surgery
n5:obor
n14:FA
n5:pocetDomacichTvurcuVysledku
2
n5:pocetTvurcuVysledku
8
n5:rokUplatneniVysledku
n13:2010
n5:svazekPeriodika
38
n5:tvurceVysledku
Škorpil, Jiří Harringer, Wolfgang Ostrovsky, Yuri Sabol, František Hausmann, Harald Hájek, Tomáš Böning, Andreas El-Essawi, Aschraf
n5:wos
000279744400017
s:issn
1010-7940
s:numberOfPages
7
n10:doi
10.1016/j.ejcts.2010.01.035
n18:organizacniJednotka
11140